Open Accessibility Menu
Hide

Lung

Study Name: Destiny Lung 04

  • Cancer Stage: III or IV
  • Key Inclusion: Non-Squamous NSCLC; HER2+ in exons 19 or 20
  • Description: A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/​Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
  • Study Number: D967SC00001
  • NCT#: NCT05048797

Study Name: Henlius

  • Cancer Stage: I-III
  • Key Inclusion: LS-SCLC; treatment naïve
  • Description: A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
  • Study Number: HLX10-020-SCLC302
  • NCT#: NCT05353257

Study Name: CYBRID-01

  • Cancer Stage: I-III
  • Key Inclusion: CT guided Bx
  • Description: Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-01)for Participants with Stage IV Lung Cancer.
  • Study Number: ELEP-2022-CYBRID-01
  • NCT#: NCT05478538

Study Name: Tempus Gemini

  • Cancer Stage: All
  • Key Inclusion: Cohort 1: Known/suspected NSCLC w/curative intent; Cohort 2: Stage IV
  • Description: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC).
  • Study Number: Tempus Gemini
  • NCT#: NCT05236114

Study Name: SOHO 02

  • Cancer Stage: III or IV
  • Key Inclusion: NSCLC with HER2 mutations
  • Description: A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)
  • Study Number: SOHO-02
  • NCT#: NCT06452277

Study Name: PACIFIC-8

  • Cancer Stage: III
  • Key Inclusion: Unresectable; concurrent chemo radiation
  • Description: A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable Non-small cell Lung Cancer
  • Study Number: D9075C00001
  • NCT#: NCT05211895

Study Name: Teligene

  • Cancer Stage: III or IV
  • Key Inclusion: NSCLC; EGFR +
  • Description: A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non Small Cell Lung Cancer
  • Study Number: TL-EGFR-2201
  • NCT#: NCT06010329

Study Name: TROPION-Lung10

  • Cancer Stage: III or IV
  • Key Inclusion: Non-Squamous NSCLC with PD-L1+; no actionable mutations
  • Description: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous Non Small Cell Lung Cancer With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
  • Study Number: D7632C00001
  • NCT#: NCT06357533

Study Name: Teligene

  • Cancer Stage: III or IV
  • Key Inclusion: NSCLC; non-resistantUncommon EGFR +
  • Description: Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
  • Study Number: SZCT-2020-06
  • NCT#: NCT05168566

Study Name: Triton

  • Cancer Stage: IV
  • Key Inclusion: Non-Squamous NSCLC; STK11, KEAP1, or KRAS mutations; no ALK
  • Description: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
  • Study Number: D419ML00003
  • NCT#: NCT06008093

Study Name: GEMINI-NSCLC

  • Cancer Stage: I-III
  • Key Inclusion: NSCLC
  • Description: NSCLC Biomarker Study
  • Study Number: TP-CA-002
  • NCT#: NCT05236114

Study Name: Tale EAP

  • Cancer Stage: IV
  • Key Inclusion: NSCLC; ROS1+
  • Description: Expanded Access Program of Taletrectinib in Patients with Advanced or Metastatic ROS1-Positive NSCLC
  • Study Number: AB-106-EAP
  • NCT#: NCT06841874

Study Name: RASolve 301

  • Cancer Stage: IV
  • Key Inclusion: NSCLC, KRAS, NRAS, HRAS
  • Description: Study of Daraxonrasib (RMC-6236) in Previously Treated Patients With RAS Mutated NSCLC
  • Study Number: RMC-6236-301
  • NCT#: NCT06881784

For more information, call 240-566-4100

All Locations